Hyperfine Announces First Patients Enrolled in PRISM PMR Study to Evaluate Swoop System Use in Operating Room Setting

Hyperfine has announced the first patients enrolled in PRISM PMR to evaluate the use of its Swoop system in the operating room setting. The study aims to collect data and optimize the system's real-world clinical utility in neurosurgical procedures. The study will evaluate the pre- and post-procedure use of portable MRI and its ability to detect post-operative complications and improve surgical workflows.

Hyperfine, Inc. (Nasdaq: HYPR) has announced the enrollment of the first patients in the PRISM PMR (PRe- and post-operatIve Study of iMaging with Portable MR) study, marking a significant step in evaluating the clinical utility of its Swoop® system in the operating room setting. The study aims to collect data and optimize the system's real-world clinical utility in neurosurgical procedures.

The PRISM PMR study, led by Dr. Elad Levy, MD, MBA, a globally recognized pioneer in neurovascular disease, is designed to assess the pre- and post-procedure use of portable MRI across a diverse range of neurosurgical procedures. The study will evaluate the ability of the Swoop® system to detect post-operative complications, such as stroke and bleeding, and how it can be best integrated into the surgical workflow to accelerate discharge and recovery. The study is being conducted over three months at the Atlas Surgery Center in Buffalo, New York.

Hyperfine President and Chief Executive Officer Maria Sainz commented, "The operating room is an exciting new setting and use case for the portable MRI market. Having a high-field MRI right in the OR is not practical. The PRISM PMR study and Dr. Levy’s pioneering work illustrate how the Swoop® system can potentially reshape neurosurgical care, bringing valuable clinical insights and workflow benefits." Dr. Levy added, "Portable brain MRI allows us to confirm results, rule out major complications, and potentially safely discharge patients on the same day. This technology has the potential to redefine surgical workflows and change how we care for patients."

The study is part of Hyperfine's mission to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. The Swoop® system is the first FDA-cleared, portable, ultra-low-field magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. For more information, visit HyperfineMRI.com.